Denali Therapeutics Inc. — Director's Dealing 2022

Jan 8, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2022-01-05

Reporting Person: Ho Carole (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-05	Common Stock	S	2845	$44.78	Disposed	163285	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	25000	Indirect
Common Stock	99816	Direct

Footnotes

F1: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.

F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.5101 to $45.05 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3: Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 7500 restricted stock units held by the Reporting Person.

F4: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.

F5: The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.

F6: Includes 99,406 restricted stock units.